News · 2026-04-30 · Casper, Wyoming

Nightbox LLC выпускает открытые in silico design notes и methodology для NKG2D-LIF6 chimera gene therapy candidate

Methods, references, и source repository выпущены под CC BY 4.0. WebXR molecular viewer опубликован. Wet-lab validation запланирован Q3-Q4 2026; pre-IND meeting target H2 2026.

CASPER, Wyo., 30 апреля 2026 — Nightbox LLC сегодня выпустил полный computational design package для NKG2D-LIF6, своего lead chimeric receptor-effector AAV9 gene therapy candidate, под CC BY 4.0 open-science license. Релиз включает architectural design notes, named-tool methodology, primary literature references, и interactive 3D molecular viewer NKG2D-MICA recognition complex.

NKG2D-LIF6 — это 2,123 base-pair gene therapy construct, combining human NKG2D extracellular domain — natural-killer cell activating receptor который binds tumor-associated stress ligands MICA и MICB — с elephant LIF6 mitochondrial pro-apoptotic effector. LIF6 — re-functionalized leukemia-inhibitory-factor pseudogene implicated в elephant cancer-resistance phenotype за Peto's paradox (Vazquez et al. 2018, Cell Reports). Delivered as single AAV9-encoded payload, construct designed to be tumor-restricted на recognition layer и apoptosis-inducing на effector layer, исключая нужду autologous cell processing характерного для CAR-T therapies.

"Point of releasing methodology now, перед wet-lab data lands — independent critique," сказал Артём Шакин, founder и CEO Nightbox LLC. "Если in silico architecture wrong где-то, мы хотим узнать перед commit любых pre-IND money to validating it."

Released materials включают:

chimera-design-notes — public source repository на github.com/nightbox-llc/chimera-design-notes covering construct architecture, named computational tools (AlphaFold3, RoseTTAFold all-atom, PyMOL, Rosetta refinement), и primary literature references
WebXR molecular viewer на nightboxllc.com/ru/3d rendering NKG2D-MICA crystal structure (PDB 1HYR) interactively в browser, с VR/AR support на Meta Quest, Vision Pro, и AR-capable mobile
Updated preprint на nightboxllc.com/ru/preprint с full computational methods, predicted ~99% TGI ceiling на syngeneic colorectal models, и explicit stage disclosure (in silico only)
Federal capability statement на capability-statement для SBIR/STTR/ARPA-H/BARDA contracting officers

Wet-lab validation на трёх syngeneic murine tumor models (colorectal, melanoma, pancreatic) запланирован для Q3-Q4 2026, с pre-IND meeting на FDA Center for Biologics Evaluation and Research targeted для H2 2026 и IND-enabling Phase 1 first-in-human dose escalation в 2027.

Компания зарегистрирована в Wyoming, операции в Greater Los Angeles area, и currently bootstrapped без outside capital. Pre-seed round $3M-$5M откроется в Q3 2026; Scientific Advisory Board формируется с четырьмя open seats published на /ru/advisors.

О Nightbox LLC

Nightbox LLC — computational biology и gene therapy компания founded в феврале 2026 Артёмом Шакиным (Wikidata Q139590669, ORCID 0009-0006-0003-6806). Зарегистрирована в Wyoming (EIN 39-4373044, Wyoming SOS entity 2025-001768533, SAM.gov UEI UHCAB6UXXKF2, CAGE 20BA7), операции из Greater Los Angeles area, runs AI-augmented R&D loop на production Anthropic SDK + AlphaFold3 + custom prompt-router stack. Nightbox committed к open-science publication in silico methodology под CC BY 4.0.

Forward-looking statements

Все preclinical claims в этом релизе — computational predictions. В обращении находится in silico data; in vivo data, human clinical data, и peer-reviewed publication NKG2D-LIF6 chimera ожидаются. Forward-looking statements о future products, regulatory pathways, clinical timelines, или commercial outcomes subject to material risk.

Контакт

Press: press@nightboxllc.com
Investors: investors@nightboxllc.com
Federal: federal@nightboxllc.com
Founder: artem@nightboxllc.com